Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes.
about
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerMolecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyReverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.Axl as a mediator of cellular growth and survivalCisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cellsCollateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cellsAxl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.Induced overexpression of CD44 associated with resistance to apoptosis on DNA damage response in human head and neck squamous cell carcinoma cellsExosomes as mediators of platinum resistance in ovarian cancer.Molecular analysis of circulating tumour cells-biology and biomarkers.AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulationCooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Function of Axl receptor tyrosine kinase in non-small cell lung cancer.Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect.
P2860
Q26749110-51A9B56B-FCB7-4D1E-A21C-F60CA1FF9E01Q28070028-93C1A2EC-E4FA-4236-8C88-B5A63C9911F0Q33880574-B9111BB4-6768-4112-9697-14DA4C706609Q34619118-5F753D0E-F859-44A3-B213-10DBE2ECA8EFQ35176432-33F44CD2-2419-4064-AA68-F5EA3EE85A5CQ35602423-BAF6543E-DA42-4A3F-A4C3-C8F0F5775846Q35757958-DFAA9021-4B03-4E38-886F-51F7D8546DBFQ36021012-3945FD84-E8C0-4262-91DC-BEB5C419A045Q37588083-02F1786F-D542-4BAC-AF6B-FF9B96FE3152Q37707018-71B80D43-4C97-4A39-A5EA-70CDC8326286Q38180320-DF45DCBD-FB00-4AD6-AD14-35F987568FE1Q38743594-8787E9F9-1A02-4289-A796-C0A945502EBBQ39157476-B239D50C-B5F3-43BD-A620-898B84FC5578Q41612891-4104A71A-C53A-4196-97E1-822DB66C27D9Q48243258-95BF42F7-1EDA-42A4-BFDF-6E586B802BBDQ49636410-EF74D780-8CE9-4B1E-9EDE-87634AECAD20Q55111008-64B245E3-0B9F-4C2D-937B-B408A49174E8
P2860
Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cisplatin influences acquisiti ...... hymal transition-like changes.
@en
Cisplatin influences acquisiti ...... hymal transition-like changes.
@nl
type
label
Cisplatin influences acquisiti ...... hymal transition-like changes.
@en
Cisplatin influences acquisiti ...... hymal transition-like changes.
@nl
prefLabel
Cisplatin influences acquisiti ...... hymal transition-like changes.
@en
Cisplatin influences acquisiti ...... hymal transition-like changes.
@nl
P2093
P2860
P356
P1433
P1476
Cisplatin influences acquisiti ...... hymal transition-like changes.
@en
P2093
Katsutoshi Goishi
Kazuya Omi
Maki Kurokawa
Nobuyuki Ise
Shigeki Higashiyama
P2860
P304
P356
10.1111/CAS.12171
P577
2013-05-15T00:00:00Z